ArticleNeuro-oncology advances

Erratum to: Characterizing Benefit from Temozolomide in MGMT Promoter Unmethylated and Methylated Glioblastoma: A Systematic Review and Meta-analysis.

Iyad Alnahhas et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.